Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes

BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is rapidly becoming the leading indication for liver transplant and is associated with increased cardiovascular and liver mortality, yet there are no licensed therapies. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are widely used fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Marjot, Thomas, Green, Charlotte J, Charlton, Catriona A, Cornfield, Thomas, Hazlehurst, Jonathan, Moolla, Ahmad, White, Sarah, Francis, Jane, Neubauer, Stefan, Cobbold, Jeremy FL, Hodson, Leanne, Tomlinson, Jeremy W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273735/
https://www.ncbi.nlm.nih.gov/pubmed/32514450
http://dx.doi.org/10.1002/jgh3.12274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273735/
https://www.ncbi.nlm.nih.gov/pubmed/32514450
http://dx.doi.org/10.1002/jgh3.12274

Ejemplares similares